Abbott Laboratories is set to unveil its third-quarter 2025 financial results next month, with investors eyeing whether the healthcare giant can maintain its momentum after a strong first half of the year.
The company announced it will release its Q3 2025 results on Wednesday, October 15, before markets open, followed by a live earnings conference call at 8 a.m. Central time (9 a.m. Eastern). The call will be accessible through Abbott’s Investor Relations website for those wanting to hear directly from executives about the quarter’s performance.
Building on Strong Momentum
Can Abbott maintain its impressive growth trajectory? The global healthcare leader, which employs over 114,000 people serving patients in more than 160 countries, delivered notable results in Q2. The company reported high single-digit organic sales growth of approximately 7%, alongside double-digit EPS growth and expanded margins.
“Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline,” said Robert B. Ford, chairman and chief executive officer of Abbott, following the Q2 results.
The company’s medical devices segment has been a particular bright spot. Worldwide Medical Devices sales increased 13.4% on a reported basis and 12.2% organically in the second quarter, with diabetes care technologies leading the charge. Sales of Abbott’s continuous glucose monitors reached a remarkable $1.9 billion, growing 21.4% on a reported basis and 19.6% organically.
Product Portfolio Driving Growth
Abbott’s diverse portfolio spans diagnostics, medical devices, nutritionals, and branded generic medicines. Several standout products have fueled the company’s recent success. Double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology businesses has been driven by products including the FreeStyle Libre® continuous glucose monitoring system, Navitor® transcatheter aortic valve, TriClip® tricuspid valve repair system, and AVEIR® leadless pacemaker.
The upcoming earnings call will likely spotlight these growth drivers, as well as provide insight into Abbott’s pipeline and strategic initiatives heading into 2026. Analysts have maintained stable and growing EPS estimates for both 2025 and 2026, suggesting continued confidence in the company’s trajectory.
That said, investors will be watching carefully for any signs of slowing momentum in key segments or commentary on macroeconomic headwinds that could impact healthcare spending globally. The company’s guidance for the remainder of 2025 will be particularly scrutinized.
For those unable to join the live webcast on October 15, Abbott will make a recorded version available later the same day through its Investor Relations website. The quarterly results will provide crucial insights into not just Abbott’s performance, but potentially broader trends across the healthcare sector as the industry navigates evolving patient needs and technological advancements.
